News | February 07, 2023
Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022
The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022
The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
